ReviewTherapeutic advances in hematology2026
High-altitude polycythemia: State-of-the-art review.
Review in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review summarizes the research progress on high-altitude polycythemia (HAPC). At the fundamental theoretical level, it provides an in-depth analysis of the epidemiological characteristics influenced by factors such as altitude, genetics, and gender, as well as the pathological mechanisms triggered by chronic hypoxia, including alterations in gene expression, immune imbalance, and disorders of iron metabolism. In the section on clinical manifestations and diagnosis, the multisystem symptoms are elaborated in detail, diagnostic criteria based on hematological indicators combined with high-altitude residence history are clarified, and the key points for differentiating HAPC from primary and other secondary polycythemia are summarized. Regarding treatment strategies, the current application and efficacy of pharmaceutical interventions, non-pharmaceutical methods such as therapeutic erythrocytapheresis (TE), and comprehensive treatment regimens are outlined. Technological advancements focus on genetic research, biomarker development, and imaging technology innovation, providing support for precise diagnosis and treatment. A review of historical development and current status reveals the evolution of research, clarifies present trends in disease prevalence, and identifies challenges in diagnosis and treatment. In the outlook for the future, innovative preventive strategies are proposed, including health education, genetic screening, and the development of novel drug formulations. The research direction of multidisciplinary integration is emphasized, such as elucidating the gene-environment interaction mechanism and developing targeted drugs. Meanwhile, controversial issues including understanding of etiology, evaluation of treatment efficacy, and ethical and social implications, aiming to provide a systematic reference for HAPC research and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.